EP1521756A1 - Heterocyclisch substituierte imidazotriazine - Google Patents
Heterocyclisch substituierte imidazotriazineInfo
- Publication number
- EP1521756A1 EP1521756A1 EP03738083A EP03738083A EP1521756A1 EP 1521756 A1 EP1521756 A1 EP 1521756A1 EP 03738083 A EP03738083 A EP 03738083A EP 03738083 A EP03738083 A EP 03738083A EP 1521756 A1 EP1521756 A1 EP 1521756A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- alkyl
- compounds
- salts
- mmol
- solvates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the invention relates to new heterocyclically substituted imidazotriazines, processes for their preparation, and their use in the production of medicaments for
- Phosphodiesterases play an important role in regulating the concentrations of cGMP and cAMP. So far, 11 phosphodiesterase isoenzyme groups are known (PDE 1-7: Beavo et al. Mol. Pharma- col. 1994, 399-405; PDE 8-10: Soderling and Beavo Curr. Opin. Cell Biol. 2000, 12, 174- 179; PDE 11: Fawcett et al. Proc. Natl. Acad. Sci. USA 2000, 97, 3702-3707).
- the PDE 10A hydrolyzes both cAMP and cGMP (Fujishige J. Biol. Chem. 1999, 274, 18438-18445). Transcribed PDE 10A was identified primarily in the putamen and caudate nucleus regions of the brain, as well as in thyroid and testicular tissue. Compared to normal tissue, the PDE lOA-mR ⁇ A is also increasingly expressed in certain tumor tissues, such as tissues of breast, liver, colon and lung tumors.
- Parkinson's disease is a chronically progressive, neurodegenerative disease that is characterized by the loss of dopaminergic neurons of the substantia nigra.
- the main characteristics of early signs and symptoms of Parkinson's disease are rest tremor, slow movement, muscle stiffness and unstable posture.
- the current medications for Parkinson's disease are of a purely symptomatic nature, with substitution therapy with L-dopa being the most frequently used form of therapy. Neither preventive nor restorative therapies are currently available (Mendis et al., Can. J. Neurol. Sei. 1999, 26, 89-103).
- Parkinson's idiopathic disease is a chronic, progressive neurological disorder that belongs to a broader classification of neurological diseases called parkinsonism. It is clinically defined by the appearance of at least two of the four cardinal symptoms: bradykinesia, resting tremor, muscle stiffness, and postural and movement disorders.
- the idiopathic form of Parkinson's disease is pathologically characterized by the loss of pigmented nerve cells, particularly in the area of the substantia nigra of the brain.
- the idiopathic Parkinson's disease makes up about 75% of all Parkinsonism diseases. The remaining 25% of cases are referred to as atypical Parkinsonism and include clinical pictures such as multiple system
- Atrophy striatonigral degeneration, or vascular parkinsonism.
- Schizophrenia is a chronic psychiatric illness that is characterized by psychoses, so-called “negative symptoms” such as apathy and social seclusion, subtle cognitive deficits and a lack of understanding of the disease.
- No. 3,941,785 describes 2-amino-imidazo [5, l-fJ- [1,2,4] triazines as PDE inhibitors with spasmolytic activity for the treatment of asthma, bronchitis, chronic heart failure and skin diseases.
- EP-A 1 250 923 describes the use of selective PDE 10 inhibitors, such as e.g. Papaverine, used to treat central nervous system disorders such as Parkinson's disease.
- the present invention relates to compounds of the formula
- R 1 5- to 10-membered heteroaryl which contains up to 3 independently selected substituents from the group oxo, halogen, carbamoyl, cyano, Hydroxy, (d-Ce-alkyltycarbonyl, trifluoromethyl, trifluoromethoxy, nitro, C f - C 6 -alkyl, dC 6 - alkoxy and -NR 5 R 6 may be substituted,
- R 5 and R 6 independently of one another for -C 6 alkyl or
- R 5 and R 6 together with the nitrogen atom to which they are attached form a 5 to 8-membered heterocycle which may be substituted with dC 6 - alkyl or C ! -C 6 hydroxy alkyl is substituted,
- R 4 C ö -Ci ö aryl, which contains up to 3 independently selected substituents from the group halogen, formyl, carboxyl, carbamoyl, cyano, hydroxy, trifluoromethyl, trifiuoromethoxy, nitro, C 1 -C 6 alkyl, dC 6 - alkoxy, l, 3-dioxa-propane-l, 3-diyl, dC ö alkylthio and -NR R may be substituted,
- R 7 and R 8 independently of one another are hydrogen, dC 6 -alkyl or C 1 -C 6 -alkylcarbonyl,
- the compounds according to the invention can exist in stereoisomeric forms (enantiomers, diastereomers).
- the invention therefore relates to the enantiomers or diastereomers and their respective mixtures.
- the stereoisomerically uniform constituents can be isolated in a known manner from such mixtures of enantiomers and / or diastereomers.
- preferred salts are physiologically acceptable salts of the compounds according to the invention.
- Physiologically acceptable salts of compounds (I) include acid addition salts of mineral acids, carboxylic acids and sulfonic acids, e.g. Salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid,
- Physiologically acceptable salts of the compounds (I) also include salts more commonly
- Bases such as, for example and preferably, alkali metal salts (for example sodium and potassium salts), alkaline earth metal salts (for example calcium and magnesium salts) and ammonium salts, derived from ammonia or organic amines having 1 to 16 carbon atoms, for example and preferably ethylamine, diethylamine, Triethylamine, ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclohexylamine,
- alkali metal salts for example sodium and potassium salts
- alkaline earth metal salts for example calcium and magnesium salts
- ammonium salts derived from ammonia or organic amines having 1 to 16 carbon atoms, for example and preferably ethylamine, diethylamine, Triethylamine, ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclohexylamine,
- solvates are those forms of the compounds which, in the solid or liquid state, are coordinated with solution solutions. middle molecules form a complex. Hydrates are a special form of solvate, in which coordination takes place with water.
- dC 6 -alkoxy represents a straight-chain or branched alkoxy radical having 1 to 6, preferably 1 to 4, particularly preferably having 1 to 3 carbon atoms.
- Non-limiting examples include methoxy, ethoxy, n-propoxy, isopropoxy, tert-butoxy, n-pentoxy and n-hexoxy.
- dC 6 -alkyl represents a straight-chain or branched alkyl radical having 1 to 6, preferably 1 to 4, particularly preferably 1 to 3 carbon atoms.
- Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-pentyl and n-hexyl.
- (C 1 -C 6 alkyl) carbonyl stands for a straight-chain or branched alkyl carbonyl radical having 1 to 6, preferably 1 to 4, particularly preferably 1 to 3 carbon atoms.
- Non-limiting examples include acetyl, ethylcarbonyl, propylcarbonyl, isopropylcarbonyl, butylcarbonyl, isobutylcarbonyl, pentylcarbonyl and hexylcarbonyl.
- dC ⁇ -Alkyrthio represents a straight-chain or branched alkylthio radical having 1 to 6, preferably 1 to 4, particularly preferably 1 to 3 carbon atoms.
- Non-limiting examples include methylthio, ethylthio, n-propylthio, isopropylthio, tert.-
- C 6 -C ⁇ p-aryl represents an aromatic radical having 6 to 10 carbon atoms.
- Non-limiting examples include phenyl and naphthyl.
- Halogen stands for fluorine, chlorine, bromine and iodine. Fluorine, chlorine, bromine are preferred, fluorine and chlorine are particularly preferred.
- 5- to 10-membered heteroaryl represents an aromatic, mono- or bicyclic radical with 5 to 10 ring atoms and up to 5 heteroatoms selected from the series
- heteroaryl radical can be bonded via a carbon or heteroatom.
- Non-limiting examples include thienyl, furyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, pyridyl, pyrimidyl, pyridazinyl, indolyl, indazolyl, benzofuranyl, benzothiophenyl, quinolinyl, isoquinolinyl.
- 5 to 8-membered heterocycle represents a mono- or polycyclic, heterocyclic radical with 5 to 8 ring atoms and up to 3, preferably 2 heteroatoms or hetero groups from the series N, O, S, SO, SO 2 , where at least one of the heteroatoms or hetero groups is a nitrogen atom.
- 5- to 7-membered heterocyclicl is preferred.
- Mono- or bicyclic heterocyclyl is preferred.
- Monocyclic heterocyclyl is particularly preferred.
- O, N and S are preferred as heteroatoms.
- the heterocyclyl residues can be saturated or partially unsaturated. Saturated heterocyclyl residues are preferred.
- 5- to 7-membered, monocyclic saturated heterocyclyl having up to two heteroatoms from the O, N and S series is particularly preferred.
- Non-limiting examples include pyrrolinyl, piperidinyl, morpholinyl, perhydroazepinyl.
- C -C 4 cycloalkyl stands for monocyclic cycloalkyl, for example cyclopropyl and cyclobutyl.
- C i -C 6 hydroxyalkyl represents a straight-chain or branched hydroxylkyl radical having 1 to 6, preferably 1 to 4, particularly preferably 1 to 3 carbon atoms.
- Non-limiting examples include hydroxymethyl, 1- or 2-hydroxyethyl, 1-, 2- or 3-n-hydroxypropyl, 1- or 2-hydroxyisopropyl, 1-hydroxy-tert.butyl, 1-,
- Another embodiment of the invention relates to compounds of the formula (I)
- R 1 5- to 10-membered heteroaryl, which can be substituted with up to 3 independently selected substituents from the group oxo, dC 6 alkyl, Ci-C ö alkoxy and -NR 5 R 6 ,
- R, s and R independently of one another -CC 6 - alkyl or
- R 5 and R 6 together with the nitrogen atom to which they are attached form a 5 to 8-membered heterocycle optionally substituted with C ⁇ -C 6 - alkyl or substituted C ⁇ -C 6 hydroxyalkyl,
- R 4 is phenyl which may be substituted with up to 3 independently selected substituents from the group halogen, C ö alkyl and dC 6 alkoxy,
- Another embodiment of the invention relates to compounds of the formula (I)
- R 1 5- to 6-membered heteroaryl, which can be substituted with up to 3 independently selected substituents from the group oxo, -CC 6 alkyl, dC ö alkoxy and -NR 5 R 6 ,
- R and R independently of one another dC 6 - alkyl or
- R 5 and R 6 together with the nitrogen atom to which they are attached form a 5 to 8-membered heterocycle optionally substituted with C ö - substituted alkyl or C 6 hydroxy alkyl, and mean
- R 2 , R 3 , R 4 and A have the meanings given above
- Another embodiment of the invention relates to compounds of the formula (I)
- R 1 represents thienyl, furyl, thiazolyl or pyridyl, which can each be substituted with up to 2 independently selected substituents from the group oxo, d- C 6 -alkyl, dC ö -alkoxy and -NR 5 R 6 ,
- R 5 and R 6 independently of one another C 1 -C 6 alkyl or
- R 5 and R 6 together with the nitrogen atom to which they are attached form a 5 to 8-membered heterocycle which is optionally substituted with Ci-C ö alkyl or C 6 hydroxyalkyl, and mean
- R 2 , R 3 , R 4 and A have the meanings given above
- Another embodiment of the invention relates to compounds of the formula (I)
- R 1 meta-pyridyl which can be substituted with up to 2 independently selected substituents from the group oxo, dC 6 -alkyl, dC 6 -alkoxy and -NR 5 R 6 ,
- R 5 and R 6 are independently dC 6 alkyl or
- R 5 and R 6 together with the nitrogen atom to which they are attached form a 5 to 8-membered heterocycle which is optionally substituted by dC 6 -alkyl or -CC 6 -hydroxyalkyl, and R 2 , R 3 , R 4 and A have the meanings given above
- Another embodiment of the invention relates to compounds of the formula (I)
- R 2 is -C 6 alkyl
- R 1 , R 3 , R 4 and A have the meanings given above and their salts, solvates and solvates of the salts.
- Another embodiment of the invention relates to compounds of the formula (I)
- R 4 is phenyl, which can be substituted by up to 3 d-C ⁇ -alkoxy radicals, and
- R 1 , R 2 , R 3 and A have the meanings given above
- Another embodiment of the invention relates to compounds of the formula (I)
- R 4 represents 3,4,5-trimethoxyphenyl and R 1 , R 2 , R 3 and A have the meanings given above
- the invention further relates to methods for producing the invention
- inert solvents are, for example, halogenated hydrocarbons such as methylene chloride, trichloromethane, carbon tetrachloride, trichloroethane, tetrachloroethane, 1,2-dichloroethane or trichlorethylene, ethers such as diethyl ether, methyl tert-butyl ether, dioxane, tetrahydrofuran, 1,2-dimethoxyethane or diethylene glycol
- Hydrocarbons such as benzene, xylene, toluene, hexane, cyclohexane or petroleum fractions, nitroalkanes such as nitromethane, CarbonECTreester as ethyl acetate, carboxamides such as dimethylformamide, dimethylacetamide, alkyl sulfoxides such as dimethyl sulfoxide, Alkyhiitrile such as acetonitrile or heteroaromatics such as pyridine, preferably pyridine, glycol dimethyl ether, diethylene glycol dimethyl ether, tetrahydrofuran , Dioxane or dimethyl sulfoxide; a reaction without solvent in the melt is also preferred.
- carboxamides such as dimethylformamide, dimethylacetamide, alkyl sulfoxides such as dimethyl sulfoxide, Alkyhiitrile such as acetonitrile or heteroaromatics
- pyridine preferably pyridine
- Bases are, for example, alkali metal hydroxides such as sodium or potassium hydroxide, alkali metal carbonates such as cesium carbonate, sodium or potassium carbonate, alkali metal alcoholates such as sodium or potassium methoxide, sodium or potassium ethanolate or potassium tert-butoxide, amides such as sodium amide, lithium bis (trimethylsilyl ) amide, lithium diisopropylamide, organometallic compounds such as butyllithium or phenyllithium, alkali hydrides such as sodium hydride, organic amines such as DBU, triethylamine or diisopropylethylamine, preferably sodium hydride, triethylamine,
- Auxiliary reagents are, for example, potassium fluoride or dimethylaminopyridine and / or crown ether, preferably 15-crown-5, 18-crown-8 or 12-crown-4.
- the compounds (LTI) are known or can be synthesized from the corresponding starting materials analogously to known processes.
- a chlorinating agent preferably phosphorus oxychloride, phosphorus pentachloride, sulfuryl chloride and / or thionyl chloride.
- reaction is generally carried out in inert solvents, if appropriate in
- Presence of a base preferably in a temperature range from -20 ° C to 20 ° C at normal pressure (see e.g. Knutsen et al., J Chem. Soc., Perkin Trans 1, 1985, 621-630; A. Kraszewski, J. Stawinski, Tetrahedron Lett. 1980, 21, 2935).
- Preferred inert solvents are pyridine, trichloromethane, diethylphenylamine,
- Preferred bases are triethylamine, pyridine or diethylphenylamine.
- dehydration reagents e.g. Lewis acids
- suitable dehydration reagents e.g. Lewis acids
- phosphorus oxychloride, phosphopentoxide, polyphosphoric acid or methylsulfonic acid chloride e.g. phosphorus oxychloride, phosphopentoxide, polyphosphoric acid or methylsulfonic acid chloride.
- the reaction can be carried out in inert solvents, preferably in a temperature range from 40 to 80 ° C at atmospheric pressure (see e.g. Charles et al. J Chem. Soc., Perkin Trans 1, 1980, 1139).
- 1,2-dichloroethane is preferred as the inert solvent.
- R has the meaning given above and Y 1 represents halogen, preferably bromine or chlorine, or hydroxy.
- the reaction can be carried out in inert solvents, if appropriate in the presence of a base, preferably in a temperature range from 0 ° C. to 50 ° C. at atmospheric pressure.
- Tetrahydrofuran or methylene chloride are preferred as inert solvents.
- Triethylamine is preferred as the base.
- the reaction can be carried out in inert solvents, if appropriate in the presence of a base and / or condensing agents, preferably in a temperature range from 20 ° C. to 50 ° C. at atmospheric pressure.
- Condensing agents are, for example, carbodiimides such as e.g. N, N'-diethyl, N, N, '- dipropyl, N, N'-diisopropyl, N, N'-dicyclohexylcarbodiimide, N- (3-dimethylamino-isopropyl) -N'-ethylcarbodiimide hydrochloride (EDC ), N-cyclohexylcarbodiimide-N'-propyloxymethyl-polystyrene (PS-carbodiimide), carbonyl compounds such as
- Bases are, for example, alkali carbonates, for example sodium or potassium carbonate or bicarbonate, or organic bases such as trialkylamines, for example triethylamine, N-methylmo ⁇ holin, N-methylpiperidine, 4-dimethylaminopyridine or diisopropylethylamine.
- alkali carbonates for example sodium or potassium carbonate or bicarbonate
- organic bases such as trialkylamines, for example triethylamine, N-methylmo ⁇ holin, N-methylpiperidine, 4-dimethylaminopyridine or diisopropylethylamine.
- VLT The compounds (VLT) are known or can be synthesized from the corresponding starting materials analogously to known processes.
- R 1 and R 3 have the meanings given above,
- the reaction can be carried out in inert solvents, preferably in a temperature range from 20 ° C. to 100 ° C. at normal pressure.
- inert solvents preferably in a temperature range from 20 ° C. to 100 ° C. at normal pressure.
- inert solvents preferably methanol, ethanol, n-propanol, iso-propanol, n-butanol or tert-butanol, preferably methanol or ethanol, can be used.
- Acids are, for example, organic acids such as acetic acid and trifluoroacetic acid or inorganic acids such as sulfuric acid, hydrogen chloride and hydrogen bromide or mixtures thereof, optionally with the addition of water; hydrogen chloride or hydrogen chloride / water is particularly preferred.
- R 1 has the meaning given above
- R and R have the meanings given above and R 9 represents (dC 4 ) alkyl, preferably methyl or ethyl, are reacted.
- the implementation of the first stage can be carried out in inert solvents, preferably in a temperature range from -10 ° C to 50 ° C at normal pressure (see e.g. K.M.
- the second stage can be reacted in inert solvents, preferably in a temperature range from 20 to 120 ° C. at atmospheric pressure.
- Inert solvents are, for example, alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol or tert-butanol, carboxamides such as dimethylformamide or alkyl sulfoxides such as dimethyl sulfoxide; methanol or ethanol are preferred.
- alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol or tert-butanol
- carboxamides such as dimethylformamide or alkyl sulfoxides such as dimethyl sulfoxide
- methanol or ethanol are preferred.
- the compounds (Va) can be prepared using compounds (ViTi) and compounds (IX),
- R 1 has the meaning given above and
- Y 2 for alkoxycarbonyl preferably methoxycarbonyl or ethoxycarbonyl, or
- Cyano stands, be implemented with trimethyl aluminum.
- reaction in straight chain hydrocarbons e.g. Hexane as an inert solvent and with the addition of ammonium salts such as ammonium chloride.
- straight chain hydrocarbons e.g. Hexane as an inert solvent
- ammonium salts such as ammonium chloride.
- the reaction can be carried out in inert solvents, preferably in a temperature range from initially at -20 ° C. and then at 20 ° C. to 80 ° C. under normal pressure (cf. e.g. for Cyano: R.S. Garigipati, Tetrahedron Lett. 1990, 31,
- Toluene is preferred as the inert solvent.
- reaction can be carried out in an alternative process with ammonium bromide or chloride and gaseous ammonia at 140 ° C to 150 ° C in an autoclave or with lithium bis (trimethylsilyl) amine and hydrogen chloride in diethyl ether (see RT Boere, et al., J Organomet. Chem. 1987, 331, 161-167).
- the compounds (X) are known or can be synthesized from the corresponding starting materials analogously to known processes.
- the compounds (XI) can, according to K.M. Doyle, F. Kurzer, Synthesis 1974, 583.
- R 9 has the meaning given above and
- X 1 represents halogen, preferably chlorine or bromine, are reacted.
- reaction can be carried out in inert solvents, if appropriate in the presence of
- Base and / or a catalyst such as dimethylaminopyridine preferably in one Temperature range from 20 to 80 ° C at normal pressure (see, for example, Charles, J Chem. Soc., Perkin Trans. 1, 1980, 1139).
- Preferred inert solvents are tetrahydrofuran or diethyl ether.
- X 2 represents halogen, preferably chlorine or bromine, are reacted.
- reaction can be carried out in inert solvents, if appropriate in the presence of a
- Base and trimethylsilyl chloride preferably in a temperature range of -10 to 60 ° C at normal pressure.
- the preferred inert solvent is methylene chloride.
- Bases are, for example, alkali metal hydroxides such as sodium or potassium hydroxide, optionally in a mixture with water, alkali metal carbonates such as cesium carbonate,
- alkali alcoholates such as potassium tert-butoxide
- amides such as sodium amide, lithium bis (trimethylsilyl) amide, lithium diisopropylamide, organic amines such as DBU, triethylamine, pyridine, piperidine or diisopropylethylamine, preferably triethylamine, sodium or potassium hydroxide in a mixture with water.
- Functional groups may be protected during the synthesis by protective groups which can subsequently be split off again (cf. e.g.
- the compounds according to the invention show an unforeseeable, valuable spectrum of pharmacological activity. They are distinguished as PDE IOA inhibitors.
- the compounds according to the invention can be used alone or in combination with other medicaments for the treatment and / or prevention of Parkinson's disease, in particular idiopathic Parkinson's disease, and of cancer diseases, in particular tumors, and for the treatment of schizophrenia be used.
- Idiopathic Parkinson's disease see is a chronic, progressive neuro- logical ⁇ disorder that belongs to a broader classification of neurological disorders, which are called Parkinsonism. It is clinically defined by the occurrence of at least two of the four cardinal symptoms: bradykinesia, resting tumor, muscle stiffness and postural and movement disorders.
- the idiopathic form of Parkinson's disease is pathologically characterized by the loss of pigmented nerve cells, particularly in the area of the substantia nigra of the brain.
- the idiopathic Parkinson's disease makes up about 75% of all Parkinsonism diseases. The remaining 25% of cases are referred to as atypical park sonism and include clinical pictures such as multiple system atrophy,
- tumors encompasses both benign and malignant tumors and thus, for example, also benign neoplasias, dysplasias, hypoplastic and neoplasms with metastasis formation.
- tumors are carcinomas, sarcomas, carcinosarcomas, tumors of the hematopoietic organs, tumors of the nerve tissue e.g. of the brain or tumors of skin cells.
- Tumor formation leads to uncontrolled or insufficiently controlled cell division.
- the tumor can be localized, but it can also infiltrate the surrounding tissue and then settle in a new location through the lymphatic system or through the bloodstream.
- Primary tumors originated in the organ in which they are found. Secondary tumors have established themselves in another organ through metastasis and then spread to their new location.
- Abnormal basal gangrene function is not only relevant for psychoses, schizophrenia and related schizoaffective disorders, but also plays a role in other neuropsychiatric changes such as depression (Kapur, Biol. Psychiatr. 1992, 32, 1-17; Lafer, et al., Psychiatric Clin North Am 1997, 20, 855-896) and
- the compounds according to the invention are suitable for the treatment of further diseases which can be treated by influencing the cGMP level and / or the cAMP level, such as dementia, stroke, traumatic brain injury, Alzheimer's disease, dementia with frontal lobe degeneration, Lewy
- Body dementia Body dementia, vascular dementia, attention deficit syndrome, attention and concentration disorders, mood disorders, psychoses, neuroses, mania or manic-depressive disorders, Pick's disease, pain and epilepsy.
- PDE 10A (WO 01/29 199, Fig. 1A) is recombinantly expressed in full length in Sf9 insect cells (Invitrogen, Carlsbad, CA) using the Bac-to-Bac TM baculovirus expression system from Life Technologies (Gaithersburg, MD). The cells are harvested 48 hours after the infection and in 20 mL (per IL culture) lysis buffer
- test substances are dissolved in 100% DMSO and serially diluted. Typically, dilution series from 200 ⁇ M to 1.6 ⁇ M are produced (resulting final concentrations in the test: 4 ⁇ M to 0.032 ⁇ M). 2 ⁇ L of the diluted substance solutions are placed in the wells of microtiter plates (Isoplate; Wallac Inc., Atlanta, GA) sets. Then 50 ⁇ L of a dilution of the PDE 10A preparation described above are added.
- the dilution of the PDE 10A preparation is chosen so that less than 70% of the substrate is converted during the later incubation (typical dilution: 1: 10000; dilution buffer: 50 mM Tris / HCl pH 7.5, 8.3 mM MgCl 2 , 1.7 mM EDTA, 0.2% BSA).
- the substrate [5 ', 8- 3 H] adenosine 3', 5'-cyclic phosphate (.
- 1 uCi / ul; Amersham Pharmacia Biotech, Piscataway, NJ) is 1: 2000 with assay buffer (50 mM Tris / HCl pH 7.5, 8.3 mM MgCl 2 , 1.7 mM EDTA) diluted to a concentration of 0.0005 ⁇ Ci / ⁇ L.
- the enzyme reaction is finally started by adding 50 ⁇ L (0.025 ⁇ Ci) of the diluted substrate.
- the test batches are incubated for 60 min at 20 ° C. and the reaction is stopped by adding 25 ⁇ L of a suspension with 18 mg / ml yttrium scintillation proximity beads (Amersham Pharmacia Biotech., Piscataway, NJ.).
- microtitre plates are sealed with a film and left to stand at 20 ° C. for 60 min.
- the plates are then measured for 30 s per well in a Microbeta scintillation counter (Wallac Inc., Atlanta, GA).
- IC 50 values are determined on the basis of the graphical plot of the substance concentration against the percentage inhibition.
- PDE 8A (GenBank / EMBL Accession Number: AF) 56490, Fisher et al. Biochem. Biophys. Res. Commun. 1998 246, 570-577), PDE 9A (GenBank / EMBL Accession Number: NM_002606, Fisher et al. J Biol. Chem. 1998 273, 15559- 15564), PDE HA (GenBank / EMBL Accession Number: NM_016953, Fawcett et al Proc. Natl. Acad. Sei 2000 97, 3702-3707) were determined using the pFASTBAC
- Baculovirus expression system (GibcoBRL) expressed in Sf9 cells.
- the neuroleptic haloperidol is a high affinity antagonist on the dopamine D2 receptor.
- the administration of a higher dose of haloperidol causes a transient blockade of dopaminergic neurotransmission. This blockage leads to a disruption of extrapyramidal motor skills, so-called catalepsy, in which a given posture is maintained longer than normal.
- Animal neuroleptic catalepsy is generally considered a model for sedentary lifestyle and rigidity in Parkinson's patients (Elliott et al.,
- male rats are randomly divided into groups to which either vehicles or different dosages of the compounds to be tested are administered. Each rat receives an intraperitoneal injection of 1.5 mg / kg haloperidol. The cataleptic behavior of the animals is recorded 120 min after the haloperidol administration. The compounds to be tested are applied to the rats at such a time interval before the catalepsy test that the maximum plasma concentration is reached at the time of the behavioral test.
- 6-Hydroxydopamine (6-QH-DA) lesion in the rat
- Parkinson's disease The degeneration of the dopaminergic nigrostriatal and striatopallidal neurotransmission is the main characteristic of Parkinson's disease
- the clinical picture of Parkinson's disease can largely be simulated in an animal model in which the neurotoxin 6-OH-DA is injected intracerebrally in rats.
- male rats (Harlan Winkelmann, Germany; weight at the start of the experiment: 180-200 g) are kept under controlled conditions (air humidity, temperature) and a 12-hour light-dark cycle. If they are not in an experiment, the animals have free access to water and feed.
- the animals were given Pargyline (Sigma, St. Louis, MO, USA; 50 mg / kg ip) and desmethylimipramine hydrochloride (Sigma; 25 mg / kg ip) 30 minutes before the lesion on the day of surgery to improve the metabolism of 6-hydroxydopamine to prevent or to prevent the absorption of 6-hydroxydopamine in noradrenergic structures.
- Pargyline Sigma, St. Louis, MO, USA; 50 mg / kg ip
- desmethylimipramine hydrochloride Sigma; 25 mg / kg ip
- test animals 50 mg / kg i.p.
- test animals are fixed in a stereotactic frame.
- the lesion of the nigrostriatal neurotransmission occurs through a unilateral, single injection of 8 ⁇ g 6-OH-DA hydrobromide (Sigma, St. Louis, MO, USA), dissolved in 4 ⁇ l of a 0.01% ascorbic acid saline solution. The solution is injected slowly (1 ⁇ l / min). The coordinates of the injection are after König and
- Klippel 2.4 mm anterior, 1.49 mm lateral, 2.7 mm ventral. After the injection, the injection needle was left in situ for 5 minutes to facilitate the diffusion of the neurotoxin.
- the animals are placed on a hot plate and after the
- 6-OHDA-injured animals are divided into different treatment groups which receive either vehicles or different dosages of the compound to be investigated.
- a group of pseudo-injured animals is also carried (0.9% sodium chloride solution in water is injected instead of 6-OHDA).
- Example 16 can change the basal ganglia function in the same direction as the antipsychotic haloperidol.
- the new active compounds can be converted in a known manner into the customary formulations, such as tablets, dragées, pills, granules, aerosols, syrups, emulsions, suspensions and solutions, using inert, non-toxic, pharmaceutically suitable excipients or solvents.
- the therapeutically active compound should in each case in a concentration of about 0.5 to 90 wt .-% of
- the formulations are prepared, for example, by stretching the active ingredients with solvents and or carriers, if appropriate using emulsifiers and or dispersants, e.g. if water is used as the diluent, organic solvents can optionally be used as auxiliary solvents.
- the application is carried out in the usual way, preferably orally, transdermally or parenterally, in particular perlingually or intravenously. However, it can also be done by inhalation through the mouth or nose, for example with the aid of a spray, or topically via the skin.
- Device type MS Micromass ZQ
- Device type HPLC Waters Alliance 2790
- Eluent B acetonitrile + 0.05% formic acid
- eluent A water + 0.05% formic acid
- UV detection 210 nm.
- 29.40 g (549.7 mmol) of ammonium chloride are suspended in 200 ml of toluene in a three-necked flask with thermometer, cooler, dropping funnel and mechanical stirrer under an argon atmosphere and cooled with petroleum ether / dry ice at 0 ° C.
- 247 ml (494 mmol) of a 2 molar solution of trimethyl aluminum in hexane are added dropwise, and the mixture is stirred at room temperature until no more gas evolution is observed (approx. 1.5 hours).
- 20.0 g (183 mmol) of 3-thiophene carbonitrile are then quickly added to this mixture, and the reaction mixture is stirred at 80 ° C. overnight.
- Washed sodium chloride solution dried over sodium sulfate and concentrated.
- the material obtained is immediately dissolved in ethanol and further reacted.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10230604A DE10230604A1 (de) | 2002-07-08 | 2002-07-08 | Heterocyclisch substituierte Imidazotriazine |
DE10230604 | 2002-07-08 | ||
PCT/EP2003/006662 WO2004005291A1 (de) | 2002-07-08 | 2003-06-25 | Heterocyclisch substituierte imidazotriazine |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1521756A1 true EP1521756A1 (de) | 2005-04-13 |
Family
ID=29796186
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03738083A Withdrawn EP1521756A1 (de) | 2002-07-08 | 2003-06-25 | Heterocyclisch substituierte imidazotriazine |
Country Status (7)
Country | Link |
---|---|
US (1) | US20060166992A1 (de) |
EP (1) | EP1521756A1 (de) |
JP (1) | JP2006502984A (de) |
AU (1) | AU2003245984A1 (de) |
CA (1) | CA2491921A1 (de) |
DE (1) | DE10230604A1 (de) |
WO (1) | WO2004005291A1 (de) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006502230A (ja) * | 2002-10-11 | 2006-01-19 | サイトキネティクス・インコーポレーテッド | 化合物、組成物および方法 |
ATE432936T1 (de) | 2003-04-01 | 2009-06-15 | Smithkline Beecham Corp | Imidazotriazin verbindungen zur behandlung von krebserkrankungen |
SG132683A1 (en) * | 2003-10-15 | 2007-06-28 | Osi Pharm Inc | Imidazopyrazine tyrosine kinase inhibitors |
EP2168968B1 (de) * | 2004-04-02 | 2017-08-23 | OSI Pharmaceuticals, LLC | 6,6-bizylische ringsubstituierte heterobizyklische Proteinkinasehemmer |
AR053090A1 (es) * | 2004-07-20 | 2007-04-25 | Osi Pharm Inc | Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos |
ATE479687T1 (de) * | 2004-10-15 | 2010-09-15 | Takeda Pharmaceutical | Kinaseinhibitoren |
US8575164B2 (en) * | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
CA2660836A1 (en) | 2006-08-07 | 2008-02-21 | Incyte Corporation | Triazolotriazines as kinase inhibitors |
SI2099447T1 (sl) | 2006-11-22 | 2013-03-29 | Incyte Corporation Experimental Station E336/205 | Imidazotriazini in imidazopirimidini kot inhibitorji kinaz |
EP2250173A1 (de) * | 2008-01-18 | 2010-11-17 | OSI Pharmaceuticals, Inc. | Imidazopyrazinolderivate zur behandlung von krebs |
EP2283020B8 (de) * | 2008-05-19 | 2012-12-12 | OSI Pharmaceuticals, LLC | Substituierte imidazopyr- und imidazotriazine |
CL2009001250A1 (es) | 2008-05-21 | 2010-02-05 | Sal del acido dihidroclorico y dibencensulfonico de 2-fluoro-n-metil-4-[7-(quinolin-6-ilmetil)imidazol[1,2-b][1,2,4]1,2,4]triazin-2-il]benzamida; compuestos intermediarios; procesos de preparacion; composicion farmaceutica; y uso para tratar cancer, aterosclerosis, fibrosis pulmonar, enfermedad renal, entre otras. | |
US8513415B2 (en) | 2009-04-20 | 2013-08-20 | OSI Pharmaceuticals, LLC | Preparation of C-pyrazine-methylamines |
JP2012526138A (ja) * | 2009-05-07 | 2012-10-25 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 副腎皮質癌を治療するためのosi−906の使用 |
CA2787714C (en) | 2010-01-22 | 2019-04-09 | Joaquin Pastor Fernandez | Inhibitors of pi3 kinase |
CN102812027B (zh) | 2010-02-03 | 2015-01-07 | 因西特公司 | 作为C-MET抑制剂的咪唑并[1,2-b][1,2,4]三嗪 |
US20130131057A1 (en) | 2010-05-13 | 2013-05-23 | Centro Nacional De Investigaciones Oncologicas (Cnio | New bicyclic compounds as pi3-k and mtor inhibitors |
JP2013530951A (ja) * | 2010-05-28 | 2013-08-01 | バイオクライスト ファーマシューティカルズ, インコーポレイテッド | ヤヌスキナーゼ阻害剤としてのヘテロ環式化合物 |
CN103476757A (zh) | 2011-02-18 | 2013-12-25 | 阿勒根公司 | 作为磷酸二酯酶10(pde10a)的抑制剂的取代的6,7-二烷氧基-3-异喹啉醇衍生物 |
JP5543039B2 (ja) * | 2011-02-23 | 2014-07-09 | ファイザー・インク | 神経障害治療のためのイミダゾ[5,1−f][1,2,4]トリアジン |
JP2014231475A (ja) * | 2011-08-25 | 2014-12-11 | 田辺三菱製薬株式会社 | 新規化合物及びそのpde10阻害薬としての使用 |
WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
DK2991989T3 (en) | 2013-05-02 | 2017-07-31 | Pfizer | IMIDAZO-TRIAZINE DERIVATIVES AS PDE10 INHIBITORS |
WO2015006689A1 (en) | 2013-07-12 | 2015-01-15 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression |
US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1457873A (en) * | 1973-01-04 | 1976-12-08 | Allen & Hanburys Ltd | Imidazotriazines |
JP2004517843A (ja) * | 2000-12-13 | 2004-06-17 | バイエル アクチェンゲゼルシャフト | ピロロ[2.1−a]ジヒドロイソキノリンおよびホスホジエステラーゼ10a阻害薬としてのその使用 |
IL149106A0 (en) * | 2001-04-20 | 2002-11-10 | Pfizer Prod Inc | Therapeutic use of selective pde10 inhibitors |
DE10130151A1 (de) * | 2001-06-22 | 2003-01-02 | Bayer Ag | Neue Verwendung für PDE 10A-Inhibitoren |
DE10130167A1 (de) * | 2001-06-22 | 2003-01-02 | Bayer Ag | Imidazotriazine |
-
2002
- 2002-07-08 DE DE10230604A patent/DE10230604A1/de not_active Withdrawn
-
2003
- 2003-06-25 EP EP03738083A patent/EP1521756A1/de not_active Withdrawn
- 2003-06-25 WO PCT/EP2003/006662 patent/WO2004005291A1/de not_active Application Discontinuation
- 2003-06-25 CA CA002491921A patent/CA2491921A1/en not_active Abandoned
- 2003-06-25 JP JP2004518560A patent/JP2006502984A/ja active Pending
- 2003-06-25 AU AU2003245984A patent/AU2003245984A1/en not_active Abandoned
- 2003-06-25 US US10/519,134 patent/US20060166992A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO2004005291A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2004005291A1 (de) | 2004-01-15 |
US20060166992A1 (en) | 2006-07-27 |
DE10230604A1 (de) | 2004-01-29 |
CA2491921A1 (en) | 2004-01-15 |
JP2006502984A (ja) | 2006-01-26 |
AU2003245984A1 (en) | 2004-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004005291A1 (de) | Heterocyclisch substituierte imidazotriazine | |
EP1709043B1 (de) | Pyrrolopyridin-substitutierte benzol-derivate zur behandlung kardiovaskulärer erkrankungen | |
EP1599479A1 (de) | Substituierte imidazotriazine | |
DE60315674T2 (de) | Neue imidazopyridine und ihre verwendung | |
DE60017575T2 (de) | Trizyklische inhibitoren von poly(adp-ribose) polymerasen | |
DE60124577T2 (de) | Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer | |
EP2097419B1 (de) | Benzofuropyrimidinone als proteinkinase-hemmer | |
DE10130167A1 (de) | Imidazotriazine | |
AU2009314760B2 (en) | Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same | |
DE60030002T2 (de) | Für den adenosin-a1-a2a-und-a3-rezeptor spezifische verbindungen und verwendungen davon | |
EP2417112B1 (de) | Sulfonamid- und sulfoximin-substituierte diaryldihydropyrimidinone und ihre verwendung | |
EP1534713A1 (de) | Alkyl-substituierte pyrazolopyrimidine | |
EP1425283B1 (de) | Neue 4-aminofuropyrimidine und ihre verwendung | |
EP1515965B1 (de) | Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren | |
DE602004006379T2 (de) | Benzthiazol-3 oxide zur behandlung von proliferativen störungen | |
WO2016083276A1 (de) | Substituierte pyridobenzodiazepinon-derivate und ihre verwendung | |
DE102005024494A1 (de) | Verwendung von Cyanopyrimidinen | |
EP1467975A1 (de) | Substituierte alkyluracile und ihre verwendung | |
CA3199333A1 (en) | C-myc mrna translation modulators and uses thereof in the treatment of cancer | |
WO2002040455A1 (de) | Substituierte amidoalkyluracile und ihre verwendung als inhibitoren der poly (adp-ribose)-synthetase (pars) | |
TW202334096A (zh) | 喹唑啉衍生化合物及其用途 | |
DE10064778A1 (de) | Cyclisch substituierte Phenylamino-uracile |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050208 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
17Q | First examination report despatched |
Effective date: 20050517 |
|
DAX | Request for extension of the european patent (deleted) | ||
RBV | Designated contracting states (corrected) |
Designated state(s): DE ES FR GB IT |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: NIEWOEHNER, ULRICH DI Inventor name: YALKINOGLU, OEZKAN Inventor name: TERSTEEGEN, ADRIAN Inventor name: SCHLEMMER, KARL-HEINZ Inventor name: SCHAUSS, DAGMAR Inventor name: MAULER, FRANK Inventor name: KELDENICH, JOERG Inventor name: HINZ, VOLKER Inventor name: GERLACH, IRENE Inventor name: FRIEDL, ARNO Inventor name: BRUECKNER, DAVID Inventor name: HENDRIX, MARTIN |
|
17Q | First examination report despatched |
Effective date: 20050517 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: NIEWOEHNER, ULRICH DI Inventor name: YALKINOGLU, OEZKAN Inventor name: TERSTEEGEN, ADRIAN Inventor name: SCHLEMMER, KARL-HEINZ Inventor name: SCHAUSS, DAGMAR Inventor name: MAULER, FRANK Inventor name: KELDENICH, JOERG Inventor name: HINZ, VOLKER Inventor name: GERLACH, IRENE Inventor name: FRIEDL, ARNO Inventor name: BRUECKNER, DAVID Inventor name: HENDRIX, MARTIN |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 25/18 20060101ALI20070327BHEP Ipc: A61P 25/16 20060101ALI20070327BHEP Ipc: A61K 31/53 20060101ALI20070327BHEP Ipc: C07D 487/04 20060101AFI20070327BHEP |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: NIEWOEHNER, ULRICH DI Inventor name: YALKINOGLU, OEZKAN Inventor name: TERSTEEGEN, ADRIAN Inventor name: SCHLEMMER, KARL-HEINZ Inventor name: SCHAUSS, DAGMAR Inventor name: MAULER, FRANK Inventor name: KELDENICH, JOERG Inventor name: HINZ, VOLKER Inventor name: GERLACH, IRENE Inventor name: FRIEDL, ARNO Inventor name: BRUECKNER, DAVID Inventor name: HENDRIX, MARTIN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20070821 |